Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ...

Compass Therapeutics, Inc. is set to report fourth-quarter and full-year 2025 results on Friday, with investors focused less on the biotech’s expected loss and more on progress toward a potential ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Good morning. I’ve fallen ...

The American Depositary Shares ("ADS") of the United Kingdom-based biotech Compass Pathways plc (CMPS) are soaring today, after management announced its psychedelic drug candidate COMP006 had met the ...

LONDON & NEW YORK, February 16, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

The Brookfield-owned hyperscale developer is planning to issue asset-backed securities backed by six new, fully leased data centers in Phoenix and Toronto, according to a presale report from Moody’s ...

Compass Group PLC CPG shares slid 2.07% to £20.81 Monday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.16% to 10,386.23.